StockData
Nuvation Bio Inc. logo

Nuvation Bio Inc. (NUVB) stock

NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30101% above fair value
$3.81+0.03 (+0.79%)

Close on Nov 19, 2026Market cap $1.34BP/E –Yield –

Nuvation Bio gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Nuvation Bio's gross profit for the twelve months ending Sep 30, 2025 was $14.51M. For fiscal 2024 it was $795.00K.

Annual gross profit

PeriodPeriod endValueChange
FY2024Dec 31, 2024$795.00K–
FY2023Dec 31, 2023$0–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2025Sep 30, 2025$9.77M–
Q2 FY2025Jun 30, 2025$2.26M+2464.8%
Q1 FY2025Mar 31, 2025$990.00K–
Q4 FY2024Dec 31, 2024$1.50M–
Q3 FY2024Sep 30, 2024-$788.00K–
Q2 FY2024Jun 30, 2024$88.00K–
Q1 FY2024Mar 31, 2024$0–
Q4 FY2023Dec 31, 2023$0–
Q3 FY2023Sep 30, 2023$0–
Q2 FY2023Jun 30, 2023$0–

More Nuvation Bio figures

See a number that looks wrong?